Hiretop · May 2024
A profile article summarizing the company’s AI-driven molecular discovery mission, founder background, and early partnership/collaboration narrative.
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Junction Bioscience is a Y Combinator W24 biotechnology startup building an autonomous AI scientist / lab-in-the-loop hypothesis engine for molecular discovery, focused on neuroinflammation and immunology and combining AI with wet-lab molecular biology to pursue internal therapeutics and partnership opportunities.
Primary product
Autonomous AI scientist / lab-in-the-loop hypothesis engine for molecular discovery
Founded
2024
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
AI-driven drug discovery
Offices
10 jobs at Junction Bioscience
Business model
Stage
Pre-Seed
Total raised
$500K
Latest round
Pre-Seed · Mar 2024
Latest amount
$500K
Mar 2024 · Y Combinator
Leadership
Chief Executive Officer
Investors
Public materials describe the company as a small, creative team with the highest scientific standards, emphasizing rigorous interdisciplinary science and collaboration.
Pricing
B2B partnership / collaboration agreements
Differentiators
Competitors
Estimated revenue
Less than $1M
Hiretop · May 2024
A profile article summarizing the company’s AI-driven molecular discovery mission, founder background, and early partnership/collaboration narrative.
Y Combinator · Mar 2024
Launch post describing Junction Bioscience as a therapeutics company building an autonomous AI scientist for transformative medicine discovery, with a focus on neuroinflammation and immunology.
LinkedIn / Y Combinator · Mar 2024
YC highlighted the company’s AI scientist approach, founder Brian Petkov’s background, and the launch of Junction Bioscience in the W24 batch.